Pages that link to "Q80915141"

The following pages link to Depressive symptoms in Parkinson's disease (Q80915141):

Displaying 48 items.

• Depressogenic effects of medications: a review (Q24635465) (← links)
• Neurological diseases and pain (Q26822891) (← links)
• Neuroimaging of Parkinson's disease: Expanding views (Q28387732) (← links)
• Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease (Q29994860) (← links)
• Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine (Q33533358) (← links)
• Emotional blunting following left basal ganglia stroke: the role of depression and fronto-limbic functional alterations. (Q33605714) (← links)
• Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse (Q33987540) (← links)
• Occurrence of depression and anxiety prior to Parkinson's disease. (Q34238344) (← links)
• Neurologists’ diagnostic accuracy of depression and cognitive problems in patients with parkinsonism (Q34306196) (← links)
• Dispositional optimism, depression, disability and quality of life in Parkinson's disease. (Q34343828) (← links)
• Diagnostic accuracy and agreement across three depression assessment measures for Parkinson's disease (Q34493954) (← links)
• Stress, depression and Parkinson's disease (Q35713356) (← links)
• Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease? (Q36946063) (← links)
• High precision liquid chromatography analysis of dopaminergic and serotoninergic responses to acute alcohol exposure in zebrafish (Q37259748) (← links)
• Subthreshold depression in Parkinson's disease (Q37312897) (← links)
• Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. (Q37396722) (← links)
• kappa-Opioid receptor signaling and brain reward function (Q37455456) (← links)
• Treatment of dementia with lewy bodies (Q37552865) (← links)
• Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment (Q37771075) (← links)
• Is depression in Parkinson's Disease (PD) a specific entity? (Q37906848) (← links)
• Lewy pathology and neurodegeneration in premotor Parkinson's disease (Q38003064) (← links)
• Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease (Q38598375) (← links)
• Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease (Q38682342) (← links)
• Mathematical insights into the effects of levodopa (Q42224924) (← links)
• Drug-induced burning mouth syndrome: a new clinico-pathological entity? (Q42392289) (← links)
• Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling (Q43043563) (← links)
• Hedonic tone and its mood and cognitive correlates in Parkinson's disease. (Q45399640) (← links)
• The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease (Q47593272) (← links)
• Alteration of brainstem raphe measured by transcranial sonography in depression patients with or without Parkinson's disease (Q48076337) (← links)
• Pure psychiatric presentation of the Lewy body disease is depression--an analysis of 60 cases verified with myocardial meta-iodobenzylguanidine study (Q48188031) (← links)
• Limbic grey matter changes in early Parkinson's disease (Q48205280) (← links)
• Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats (Q48359779) (← links)
• Lewy body dementia and Parkinson's disease with dementia (Q48423144) (← links)
• Religious and spiritual beliefs in outpatients suffering from Parkinson Disease (Q48611029) (← links)
• Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? (Q48968131) (← links)
• Increased risk of Parkinson's disease following tension-type headache: a nationwide population-based cohort study (Q49704604) (← links)
• Depression in patients with Parkinson's disease and the associated features (Q50194256) (← links)
• Anhedonia in Japanese patients with Parkinson's disease: Analysis using the Snaith–Hamilton Pleasure Scale (Q50598512) (← links)
• Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats. (Q50891658) (← links)
• Early Life Stress, Depression And Parkinson's Disease: A New Approach. (Q52650242) (← links)
• Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson's disease: a systematic review (Q58104611) (← links)
• Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease (Q64235467) (← links)
• Comparison of structural connectivity in Parkinson's disease with depressive symptoms versus non-depressed: a diffusion MRI connectometry study (Q64930441) (← links)
• Depression in Parkinson’s disease (Q84074996) (← links)
• Depression in Parkinson's disease (Q87325496) (← links)
• Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test (Q90116092) (← links)
• Sensory focused exercise improves anxiety in Parkinson's disease: A randomized controlled trial (Q91986624) (← links)
• Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (Q96439071) (← links)